BC-7013: Phase I started
Nabriva began a Phase I trial of topical BC-7013. Nabriva Therapeutics Forschungs GmbH , Vienna, Austria Product: BC-7013 Business: Infectious Molecular target: NA Description: Pleuromutilin antibiotic agent Indication: Treat bacterial...
